AEterna Zentaris Inc. (AEZS)

[Investwisely123]

Can't imagine a pharmaceutical giant like Novo Nordisk only wanting the rights to Macrilen in USA and Canada. Novo Nordisk as mentioned in their October 31, 2018 press release really needs Macrilen to compliment its drug Norditropin. Therefore, Novo Nordisk will most certainly also want to acquire full worldwide rights to Macrilen outside of the USA and Canada as well. Novo Nordisk was most likely waiting to make sure that Macrilen got approved in Europe before buying out AEZS or making a huge licensing deal with AEZS for Macrilen. Now after last Fridays news, European approval of Macrilen is basically an absolute certainty within the coming weeks. Thus, to me its a no brainer that Novo Nordisk will buy out AEZS within the next two to three months from now. By buying out AEZS instead of doing a big licensing agreement for Macrilen outside of the USA and Canada, Novo Nordisk can save on the royalties it would have had to pay AEZS for the sales of Macrilen in the USA and Canada. The buyout makes the most sense for both Novo Nordisk and AEZS. http://press.novonordisk-us.com/News-Releases?item=122951